# SNIFF Multi-Device Study 2

> **NCT04199767** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 13 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Cognitive Impairment

## Interventions

- **DRUG:** 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- **DRUG:** 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)

## Key facts

- **NCT ID:** NCT04199767
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2020-11-03
- **Final completion:** 2020-11-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04199767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04199767, "SNIFF Multi-Device Study 2". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04199767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*